phathompharma.com (PHAT) - Company Sales Revenue

Corporate emblem and logo of Phathom Pharmaceuticals, Inc. (PHAT)

The commercialization of Voquezna provides Phathom Pharmaceuticals (PHAT) with a steady cash flow and high-quality earnings. The company's consolidated sales on this chart demonstrate actual revenue stripped of market noise, where the value of 0.27 expresses the metric level. Innovative drugs for acid-related pathologies enable the company to maintain pricing power. This patented blockbuster is effectively displacing legacy standards of care, expanding the issuer's market share.

Phathom Pharma (PHAT): Company Sales from 07/04/2022 to 11/15/2026

Analytical breakdowns for Phathom Pharmaceuticals

- stock price and consensus target price:
Quote Chart Phathom Pharmaceuticals|PHAT - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Phathom Pharma|PHAT - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Phathom Pharmaceuticals|PHAT - Company Net Assets|Market Cap to Book Value Multiple phathompharma.com|PHAT - Company Total Assets
- debt and solvency information:
All Debt to Shareholders' Equity Ratio Phathom Pharmaceuticals|PHAT - Long-Term Debt to Equity|Current Liabilities to Capital Phathom|PHAT - Company Debts|Debt to Book Value Phathom|PHAT - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Phathom Pharmaceuticals|Critical Liquidity Ratio phathompharma.com
- net income and valuation ratios data:
PHAT - Net Profit|Expected Net Income Phathom Pharmaceuticals|PHAT - P/E Multiple|Forward P/E Multiple Phathom Pharma|PHAT - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Phathom Corp|PHAT - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Phathom Pharmaceuticals|PHAT - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth phathompharma.com|PHAT - Earnings growth in current year|Expected earnings per share growth for next year Phathom Pharmaceuticals
- issuer revenue and sales details:
PHAT - Revenue and Sales Volume|Company Expected Sales Volume Phathom Pharmaceuticals, Inc.|PHAT - Market Cap to Revenue|Forward P/S Multiple Phathom
Comprehensive company analysis:PHAT Phathom Pharmaceuticals, Inc.
Flagship merchandise of Phathom Pharmaceuticals

For Phathom Pharmaceuticals (PHAT), whose revenue depends on a single GI drug, this indicator serves as the primary measure of commercial success. The metric aggregates all actual cash inflows from product sales over the reporting period. By analyzing the company's annual sales volume, an investor assesses the pace of insurance coverage expansion. Steady growth confirms the product's market potential, while sharp fluctuations on the chart signal systemic risks associated with a single-product model.

Competing companies

TERN (Terns Pharmaceuticals) - Company Total Sales|Company Revenue Ironwood Pharma (IRWD)|Revenue and Sales Volume Curanex Pharma (CURX)|Company Revenue Immuron Limited IMRN|Evoke Pharma Inc (EVOK) - Company Total Revenue|Entero - Revenue and Sales Volume|Company Sales Revenue RDHL (redhillbio.com)|palisadebio.com (PALI) - Company Revenue|Jaguar Health Inc (JAGX) - Revenue and Sales Volume|Company Sales BIOR|Morphic Holding Inc (MORF) - Company Gross Revenue